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Background:  Although  myocardial  interstitial  ﬁbrosis  has been  considered  to  play a  pathogenic  role
in  chronic  heart  failure  (HF),  the  role  of  perivascular  ﬁbrosis,  another  form  of  ﬁbrosis,  remains  to be
elucidated.
Methods:  We  examined  64 consecutive  patients  with  non-ischemic  HF  caused  by  hypertrophic  car-
diomyopathy  (HCM,  n = 16),  hypertensive  heart  disease  (HHD,  n  =  11),  or dilated  cardiomyopathy  (DCM,
n =  37),  diagnosed  by both  cardiac  catheterization  and  endomyocardial  biopsy  (right ventricular  side  of
the interventricular  septum)  in  the  Tohoku  University  Hospital  between  January  2001  and  April  2009.
We calculated  the  collagen  volume  fraction  (CVF)  and  perivascular  ﬁbrosis  ratio  (PFR)  in  biopsy  samples
and also  examined  Thrombolysis  in  Myocardial  Infarction  (TIMI)  frame  count  to evaluate  coronary  blood
ﬂow.
Results: There  was  no signiﬁcant  correlation  between  CVF  and  PFR  (r2 = 0.0007).  Although  CVF  was  com-
parable  among  HCM,  HHD,  and  DCM  (1.11  ± 1.04,  1.89  ±  1.61,  and  1.41 ± 1.48,  respectively),  PFR was
signiﬁcantly  higher  in HCM  than  in DCM  (1.78  ±  1.09  vs. 1.23  ±  0.44, p < 0.05).  PFR  was  not  correlated
with  cardiac  function  parameters,  such  as left ventricular  (LV)  ejection  fraction,  cardiac  output,  LV  end-
diastolic pressure,  LV  end-diastolic  volume,  aortic  pressure,  or pulmonary  artery  pressure.  However,  PFR
was  signiﬁcantly  correlated  with  coronary  ﬂow  in the  left  anterior  descending  coronary  artery  (as  evalu-
ated by  TIMI  frame  count)  (r2 = 0.3351,  p  <  0.0001,  in  all-cases  combined  population),  but  not with  that  in
the left  circumﬂex  or right  coronary  artery.  This  correlation  remained  signiﬁcant  in a logistic  regression
model  tested  in  7 variables  (body  mass  index,  PVR,  CVF,  presence  of  hypertension,  dyslipidemia,  diabetes
mellitus,  and  atrial  ﬁbrillation).
Conclusions:  These  results  indicate  that  coronary  perivascular  ﬁbrosis  is associated  with  the  impairment
of  coronary  blood  ﬂow  although  not  associated  with  interstitial  ﬁbrosis  or cardiac  function,  suggesting
that  it  can  be  a new  therapeutic  target  to improve  coronary  microcirculation.
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Chronic heart failure (HF) is a complex clinical syndrome that
an result from any structural or functional cardiac disorders,
ncluding coronary artery disease, hypertensive heart disease,
yocardial disease, and valvular heart disease [1],  where not only
F with reduced ejection fraction (HFrEF) but also HF with pre-
erved ejection fraction (HFpEF) are substantially involved [2–4].
ndeed, HFrEF and HFpEF respectively account for approximately
alf of chronic HF patients [5–8].
∗ Corresponding author at: Department of Cardiovascular Medicine, Tohoku Uni-
ersity Graduate School of Medicine, 1-1 Seiryo-machi, Aoba-ku, Sendai 980-8575,
apan. Tel.: +81 22 717 7153; fax: +81 22 717 7156.
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In HF patients, coronary ﬂow reserve is impaired during the
acute phase of HF and is strongly correlated with mortality [9,10].
Coronary microvascular dysfunction has been recognized as an
important contributor to impaired coronary blood ﬂow [11], which
occurs not only in coronary artery disease, but also in various
myocardial diseases, such as hypertension, hypertrophic cardiomy-
opathy (HCM) and inﬁltrative heart disease (e.g. Anderson–Fabry
cardiomyopathy) [11]. Also, it has been reported that myocar-
dial diseases are associated with abnormal coronary microvascular
structures such as thickened wall and proliferation of vascu-
lar smooth muscle cells [11]. However, the correlation between
organic and functional coronary microvascular abnormalities has
not been well documented.
Thrombolysis in Myocardial Infarction (TIMI) frame count is a
simple, objective, and quantitative index of coronary blood ﬂow,
and has been reported to increase not only in myocardial infarction
vier Ltd. All rights reserved.
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12], but also in coronary microvascular dysfunction [11,13–15].  It
s important to exclude the contribution of organic coronary artery
isease when evaluating coronary blood ﬂow and microvascular
ysfunction in HF patients. In the present study, we  thus aimed to
xamine the impact of perivascular ﬁbrosis on coronary microvas-
ular dysfunction in patients with chronic and non-ischemic HF by
sing TIMI frame count.
ethods
The ethical committees of Tohoku University Hospital approved
he study protocol and all patients provided written informed con-
ent.
tudy subjects
We  examined 132 consecutive patients with stages B/C/D
hronic HF deﬁned by the American College of Cardiol-
gy/American Heart Association 2005 Guidelines [1,4], caused by
on-ischemic HF, including hypertrophic cardiomyopathy (HCM,
 = 45), hypertensive heart disease (HHD, n = 25), or dilated car-
iomyopathy (DCM, n = 62) enrolled in our database, who were
ospitalized at our hospital and underwent both cardiac catheter-
zation and endomyocardial biopsy (right ventricular side of the
nterventricular septum) to diagnose the etiology of HF from
anuary 2001 to April 2009. In the present study, 68 out of the 132
atients were excluded; 66 for the absence of coronary arteries in
he biopsy samples and 2 for signiﬁcant coronary artery disease.
inally, we enrolled the remaining 64 patients, including 16 HCM,
1 HHD, and 37 DCM patients.
ata collection
Baseline demographic data, hemodynamic data obtained by
atheterization, medications, and comorbidities (hypertension,
iabetes mellitus, dyslipidemia, and atrial ﬁbrillation) were
btained from their medical records. Hypertension was  diagnosed
y the use of antihypertensive drugs and/or systolic blood pressure
130 mmHg  and/or diastolic blood pressure ≥80 mmHg. Diabetes
ellitus was diagnosed by the use of anti-diabetic drugs, fasting
lucose ≥110 mg/dl, and/or glucose ≥200 mg/dl 2 h after a 75 g oral
lucose tolerance test. Dyslipidemia was diagnosed by the use of
ipid-lowering drugs and/or elevated lipid levels, deﬁned as plasma
ow-density lipoprotein (LDL) cholesterol ≥140 mg/dl, triglyc-
rides ≥150 mg/dl, or high-density lipoprotein (HDL) <40 mg/dl.
he hemodynamic parameters obtained by cardiac catheterization
ncluded left ventricular ejection fraction (LVEF), LV end-diastolic
olume index (LVEDVI), aortic pressure (AoP), LV end-diastolic
ressure (LVEDP), pulmonary artery pressure (PAP), pulmonary
apillary wedge pressure (PCWP), cardiac output (CO) and cardiac
ndex (CI). Before cardiac catheterization, we measured serum lev-
ls of hemoglobin, brain natriuretic peptide (BNP), creatinine, and
igh-sensitivity C-reactive protein (hsCRP), and estimated creati-
ine clearance (eGFR) by Cockroft–Gault formula.
istological analysis of biopsy samples
The acquisition, ﬁxation, and staining of myocardial biopsy sam-
les was previously described [16]. Collagen volume fraction (CVF),
s an index of myocardial interstitial ﬁbrosis, was calculated and
veraged in representative ﬁelds containing no endocardium or
lood vessel, as previously described [16].
Furthermore, we have analyzed images of the stained sec-
ions using ImageJ 1.45 s (W.  Rasband, NIH, Bethesda, MD,  USA,
ttp://imagej.nih.gov/ij/, 1997–2012, 400×) to determine perivas-
ular ﬁbrosis around arteries, expressed as perivascular ﬁbrosisogy 60 (2012) 416–421 417
ratio (PFR) (Fig. 1). PFR was deﬁned as the area of perivascular
ﬁbrosis divided by the area of the vascular wall, averaged over all
quantiﬁable images of arteries taken from a section [17] (mean,
1.72 ± 0.84 quantiﬁable images of arteries). All histological eval-
uation was  performed by a single well-trained observer without
knowing whose samples were analyzed.
Determination of delayed enhancement on cardiac magnetic
resonance imaging
Out of the 64 patients enrolled, 27 also underwent cardiac
magnetic resonance (CMR) imaging using a 1.5-T CMR  system
(Siemens Magnetom, Erlangen, Germany). Delayed enhancement
images captured 15 min  after intravenous injection of gadolinium
were used to determine the presence of delayed enhancement
[18–20].
Evaluation of coronary blood ﬂow
Coronary blood ﬂow was quantiﬁed by a single well-trained
observer in a blind manner, using TIMI frame count (TFC) method
[12]. TFC was determined separately for the left anterior descending
(LAD) and circumﬂex coronary artery (LCx), and the right coro-
nary artery (RCA), according to the method described by Gibson
et al. [12]. We  calculated corrected TFC (CTFC) for LAD by divid-
ing TFC by 1.7, in order to adjust that for LCx and RCA [12]. All
coronary angiograms were obtained before endomyocardial biopsy
at a speed of 15 frames/s. To be universally comparable, TFCs and
CTFCs were converted to a frame acquisition rate of 30 frames/sec
by multiplying by 2.0 [15].
Statistical analysis
Continuous variables were presented as mean ± SD. Comparison
of 2 groups was  made by unpaired t-test for continuous variables
and Pearson’s chi-square test for categorical variables. Comparison
among 3 groups was made by ANOVA test. A multivariate analysis
was conducted to examine the effectors of CTFC for LAD, using a
logistic regression model, in which the following were included as
variables: body mass index (BMI), PFR, CVF, and the presence of
comorbidities (hypertension, dyslipidemia, diabetes mellitus, and
atrial ﬁbrillation). A p-value less than 0.05 was considered to be
statistically signiﬁcant.
Results
Patient characteristics
There were no statistically signiﬁcant differences among the 3
groups in age, gender, or BMI  (Table 1). Expectedly, the prevalence
of hypertension was signiﬁcantly higher in the HHD group com-
pared with the other 2 groups (Table 1). The DCM group had a higher
prevalence of atrial ﬁbrillation than the HCM group (Table 1). LVEF
was the highest in the HCM group (Table 1).
Coronary perivascular ﬁbrosis and myocardial interstitial ﬁbrosis
Although there was  no signiﬁcant difference in myocardial
interstitial CVF among the 3 groups (Fig. 2A), PFR was signiﬁcantly
more severe in the HCM group than in the DCM group (Fig. 2B). No
correlation was observed between CVF and PFR in all-cases com-
bined population (Fig. 2C) or in each group (Fig. 2D–F). Of the 27
patients who underwent CMR, 16 presented delayed enhancement
and PFR was comparable between the patients with and those with-
out delayed enhancement (1.18 ± 0.67 vs. 1.55 ± 0.78, p = 0.21).
418 Z. Dai et al. / Journal of Cardiology 60 (2012) 416–421
Fig. 1. Representative histology of perivascular ﬁbrosis. Perivascular ﬁbrosis in hypertrophic cardiomyopathy (HCM) (left), hypertensive heart disease (HHD) (middle), and
d  staini
C
p
L
p
(
c
c
(
p
a
p
m
F
(
pilated  cardiomyopathy (DCM) (right) patients, stained in blue by Elastica–Masson
oronary perivascular ﬁbrosis and cardiac function
PFR was not signiﬁcantly correlated with LVEF (r2 = 0.0003,
 = 0.90), CO (r2 = 0.0095, p = 0.45), LVEDP (r2 = 0.0042, p = 0.62),
VEDV (r2 = 0.0019, p = 0.75), systolic and diastolic AoP (r2 = 0.0038,
 = 0.63; r2 = 0.0102, p = 0.43, respectively), systolic or diastolic PAP
r2 = 0.0102, p = 0.43; r2 = 0.0072, p = 0.51, respectively), in all-cases
ombined population as well as in each group. The prognosis was
omparable between mild and severe perivascular ﬁbrosis groups
divided by the median of 1.255), for all-cause death (log-rank test,
 = 0.49) or cardiac events, including cardiac or sudden death and
dmission for HF (log-rank test, p = 0.29), as was the case with
atient characteristics such as gender, age, BMI, comorbidities,
edication, and laboratory data (data not shown).
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Perivascular ﬁbrosis and TIMI frame count
TFCs measured in each group are shown in Table 2. There were
no signiﬁcant differences among the 3 groups in each coronary
artery. Importantly, PFR was signiﬁcantly correlated with CTFCs for
LAD (Fig. 3A), but not with those for LCx or RCA (Fig. 3B and C). The
correlation between PFR and CTFC for LAD was also observed in
each group (Fig. 3D–F). Multivariate analysis was  performed using
a logistic regression model to examine the difference between high
and low CTFC for LAD (divided by median of 21.18, with median
attributed into the lower group) with 7 comorbidities, demonstrat-
ing that only PFR and atrial ﬁbrillation were signiﬁcantly correlated
with CTFC for LAD (Table 3). PFR in patients with and without atrial
ﬁbrillation were comparable (1.42 ± 0.53 vs. 1.45 ± 0.91, p = 0.92).
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iscussion
The novel ﬁndings of the present study are as follows: (1)
lthough interstitial CVF was comparable among the HCM, HHD,
nd DCM groups, perivascular ﬁbrosis was more severe in the HCM
roup than in the DCM group; (2) PFR was independent of CVF;
nd (3) PFR was signiﬁcantly correlated with CTFC for LAD. To the
est of our knowledge, this is the ﬁrst report that demonstrates
he histopathological impact of perivascular ﬁbrosis of small coro-
ary arteries on impaired coronary blood ﬂow in non-ischemic HF
atients. Thus, the present results suggest that impaired coronary
icrocirculation could be caused not only by vascular remodeling,
ndothelial dysfunction, and microvascular spasm [11,21], but also
y perivascular ﬁbrosis.
oronary perivascular ﬁbrosis and interstitial myocardial ﬁbrosis
Several studies have shown that myocardial collagen content is
orrelated with LV stiffness [22,23] and is involved in the progres-
ion of HF [24–26].  We  also have recently demonstrated that CVF
s correlated with LVEDP in HFrEF and is an important predictor of
oor prognosis [16]. Previous studies using autopsy samples have
emonstrated that interstitial CVF was higher in HCM than in HHD
27,28] and that ventricular ﬁbrosis in HCM is known to concentrate
n the ventricular septum, whereas it is equally distributed in the
eptum and the LV free wall in HHD [27]. The present study demon-
trates that interstitial CVF was comparable between HCM and
HD, probably because our biopsy samples were obtained from the
entricular septum. Compared with interstitial myocardial ﬁbro-
is, not much attention has been paid to the possible importance of
erivascular ﬁbrosis in the pathogenesis of non-ischemic HF.
As demonstrated in the present study, neither CVF nor delayed
nhancement on CMR  was correlated with perivascular ﬁbrosis.M, hypertrophic cardiomyopathy; HHD, hypertensive heart disease; DCM, dilated
Furthermore, no correlation was observed between PFR and cardiac
function such as LVEF, CO, or LVEDP. These results suggest that
coronary perivascular ﬁbrosis occurs independently of interstitial
myocardial ﬁbrosis or cardiac function.
Coronary perivascular ﬁbrosis and coronary blood ﬂow
TFC is a simple, effective and quantitative index of coronary
blood ﬂow that is able to detect coronary microvascular dysfunc-
tion [11–15].  The present study demonstrates for the ﬁrst time
the signiﬁcant correlation between PFR and CTFC for LAD, indicat-
ing that perivascular ﬁbrosis is substantially associated with the
impairment of coronary blood ﬂow in patients with non-ischemic
HF.
In the present study, PFR in biopsy samples from the septum
was associated with CTFC for LAD, but not TFC for LCx or RCA. This
ﬁnding appears to be reasonable as blood ﬂow in the septum is sup-
plied mainly by LAD [29]. As the present study indicated, PFR in the
area supplied by LAD was signiﬁcantly associated with CTFC. Thus,
if we could examine PFR in the free walls supplied by LCx or RCA,
PFR in such areas might be associated with TFC in the correspond-
ing areas. Conversely, this ﬁnding also suggests that the evaluation
of perivascular ﬁbrosis of the septum does not reﬂect that of the
whole heart.
In addition to PFR, the presence of atrial ﬁbrillation, which was
irrelevant to PFR, was also signiﬁcantly correlated with CTFC for
LAD, a consistent ﬁnding with the previous study that atrial ﬁb-
rillation was  associated with increased coronary resistance and
impaired myocardial blood ﬂow [30]. The present study did not
show that hypertension, diabetes mellitus, and dyslipidemia were
related to CTFC for LAD, probably due to the limited number of
patients in the present study.
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Table 1
Patient characteristics.
HCM (n = 16) HHD (n = 11) DCM (n = 37) Notes
Male gender 13 (81) 8 (73) 27 (75)
Age (years) 55.9 ± 12.4 53.4 ± 14.9 55.5 ± 13.5
BMI  (kg/m2) 24.2 ± 4.0 25.6 ± 4.8 24.7 ± 4.2
Hypertension 5 (31) 11 (100) 17 (46) *,‡
Diabetes mellitus 2 (13) 5 (45) 6 (16) ‡
Dyslipidemia 2 (13) 3 (27) 10 (27)
Atrial ﬁbrillation 1 (6) 1 (9) 14 (38) †
Medication
ACEI 6 (38) 6 (55) 22 (59)
ARB 2 (13) 8 (73) 13 (35) *,‡
-blocker 10 (63) 9 (82) 26 (70)
Diuretics 0 (0) 3 (27) 21 (57) †
Spironolactone 2 (13) 1 (9) 11 (30)
Warfarin 2 (13) 2 (18) 18 (49) †
CCB 7 (44) 6 (55) 4 (11) †,‡
Antiplatelet 4 (25) 4 (36) 10 (27)
Statin 0 (0) 1 (9) 9 (24) †
Amiodarone 0 (0) 0 (0) 4 (11)
Laboratory data
Hemoglobin
(g/dl)
14.4 ± 1.4 14.3 ± 1.9 14.3 ± 1.6
hsCRP (mg/dl) 0.10 ± 0.14 0.15 ± 0.14 0.15 ± 0.17
BNP (pg/ml) 218.7 ± 247.3 50.7 ± 33.9 240.6 ± 373.3 *
LDL (mg/dl) 77.8 ± 62.8 89.7 ± 75.0 85.2 ± 74.8
HDL (mg/dl) 56.7 ± 23.5 39.3 ± 9.4 42.0 ± 12.5 *,†
TG (mg/dl) 130.9 ± 91.9 143.9 ± 65.2 138.3 ± 74.4
Glucose (mg/dl) 94.5 ± 25.8 110.9 ± 19.5 106.4 ± 30.6
CCr (ml/min) 89.4 ± 34.4 95.5 ± 24.2 93.8 ± 37.7
Hemodynamic data
LVEDVI (ml/m2) 72.5 ± 18.3 72.7 ± 19.0 111.8 ± 28.0 †,‡
EF (%) 71.2 ± 10.1 54.4 ± 4.9 36.8 ± 11.8 *,†,‡
mAoP (mmHg) 103.8 ± 17.5 120.2 ± 19.7 98.8 ± 17.8 *,‡
LVEDP (mmHg) 16.6 ± 5.7 10.3 ± 5.1 10.6 ± 4.1 *,†
mPAP (mmHg) 19.9 ± 4.5 20.9 ± 7.0 18.9 ± 5.3
PCWP (mmHg) 11.3 ± 6.2 9.3 ± 5.0 9.0 ± 5.3
Cardiac output
(L/min)
4.7 ± 1.0 5.9 ± 1.7 4.6 ± 1.4 *,‡
Cardiac index
(L min−1 m−2)
2.7 ± 0.4 3.3 ± 0.6 2.7 ± 0.7 *,‡
Morphometric data
CVF (%) 1.11 ± 1.04 1.89 ± 1.61 1.41 ± 1.48
PFR  1.78 ± 1.09 1.63 ± 1.20 1.24 ± 0.45 †
All-cause death 1 (6) 0 (0) 2 (5)
Cardiac events
Cardiac or
sudden death
0 (0) 0 (0) 2 (5)
Admission for HF 2 (13) 0 (0) 3 (8)
Results are presented as mean ± SD or n (%). ACEI, angiotensin-converting enzyme
inhibitor; ARB, angiotensin receptor blocker; BMI, body mass index; BNP, brain
natriuretic peptide; CCB, calcium channel blocker; CCr, creatinine clearance; CVF,
collagen volume fraction; DCM, dilated cardiomyopathy; EF, ejection fraction; HCM,
hypertrophic cardiomyopathy; HDL, high-density lipoprotein; HF, heart failure;
HHD, hypertensive heart disease; hsCRP, high-sensitive C-reactive protein; LDL,
low-density lipoprotein; LVEDP, left ventricular end-diastolic pressure; LVEDVI,
left  ventricular end-diastolic volume index; mAoP, mean aortic pressure; mPAP,
mean pulmonary artery pressure; PCWP, pulmonary capillary wedge pressure; PFR,
perivascular ﬁbrosis ratio; TG, triglyceride.
* p < 0.05, HCM vs. HHD.
† p < 0.05, HCM vs. DCM.
‡ p < 0.05, HHD vs. DCM.
Table 2
Thrombolysis in myocardial infarction frame counts.
Coronary artery HCM (n = 16) HHD (n = 11) DCM (n = 37a) p-Value
LAD (corrected) 21.91 ± 5.48 22.78 ± 6.23 21.67 ± 3.87 n.s.
LCx  29.63 ± 3.80 31.82 ± 8.55 33.30 ± 11.82 n.s.
RCA  39.50 ± 15.22 34.72 ± 9.39 38.72 ± 14.64 n.s.
Results are presented as mean ± SD. HCM, hypertrophic cardiomyopathy; HHD,
hypertensive heart disease; DCM, dilated cardiomyopathy; LAD, left anterior
descending coronary artery; LCx, left circumﬂex coronary artery; RCA, right coronary
artery; n.s., not statistically signiﬁcant.
a Data of LAD in one DCM case and that of RCA in another DCM case failed to be
obtained.
Table 3
Logistic regression model for factors of corrected thrombolysis in myocardial infarc-
tion  frame count for the left anterior descending coronary artery.
Variables p-Value Odds ratio (95% CI)
Hypertension 0.23
Dyslipidemia 0.21
Diabetes mellitus 0.63
Atrial ﬁbrillation 0.02 5.78 (1.33–30.53)
Body mass index (kg/m2) 0.20
PFR <0.002 3.28 (1.52–9.00) per 1.0 increase
CVF (%) 0.8195% CI, 95% conﬁdence interval; PFR, perivascular ﬁbrosis ratio; CVF, collagen vol-
ume  fraction.
Heart failure and coronary blood ﬂow
It has been reported that coronary blood ﬂow is impaired in
aortic valve diseases because coronary blood ﬂow depends on
hemodynamic changes [31] and that coronary blood ﬂow is deter-
mined by heart rate, peak stress, and ventricular performance in
cardiomyopathy with normal coronary angiogram [32]. Coronary
microvascular dysfunction has attracted much attention as a con-
tributor to impaired coronary blood ﬂow in various etiologies of
HF [11]. The presence of microvascular dysfunction after acute
myocardial infarction is now considered to be an important prog-
nostic factor [33]. Coronary ﬂow reserve, as an indicator of coronary
blood ﬂow, has been demonstrated to be impaired during acute
phase of HF, and to be strongly correlated with the mortality of HF
patients [9,10].  Thus, it is important to improve coronary blood ﬂow
in non-ischemic HF patients as well and to pay much attention to
perivascular ﬁbrosis as it is an important determinant of coronary
blood ﬂow.
Study limitations
Several limitations should be mentioned for the present study.
First, coronary arteries in biopsy samples were partially crushed
during the procedure, which might have affected the quantita-
tive analyses of perivascular ﬁbrosis, although we did not use
the lumen area for the present analysis. Furthermore, myocar-
dial biopsy samples from healthy controls were not available for
apparent ethical reasons. Second, we  only examined the role of
perivascular ﬁbrosis quantity but not its quality. Indeed, it has
been reported that not only the quantity but also the quality of
interstitial myocardial ﬁbrosis (e.g. cross-linking and type I/III col-
lagen ratio) are important determinants of myocardial stiffness
[34–36]. Future studies are required to address this issue. Third,
we used TFC method to evaluate coronary blood ﬂow because we
did not directly evaluate coronary ﬂow velocity with a ﬂow wire.
This was  based on the previous studies that TFC well represents
coronary ﬂow velocity [12,15,37,38].  Fourth, we  were unable to
elucidate the mechanisms and factors related to perivascular ﬁbro-
sis. This issue should also be examined in future studies. Finally,
the present study was an observational study with a relatively
small number of patients. The relatively small numbers of all-cause
deaths and admissions (Table 1) prevented us from investigating
whether perivascular ﬁbrosis has a prognostic impact. This issue
also should be addressed in future studies with a large number of
patients, including the effects of drugs to modulate perivascular
ﬁbrosis.
In conclusion, we  were able to demonstrate that coronary
perivascular ﬁbrosis is signiﬁcantly associated with impairment of
coronary blood ﬂow in non-ischemic HF patients. Thus, coronary
perivascular ﬁbrosis can be a new therapeutic target to improve
coronary microcirculation in HF.
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